Combining innovative science, leading technology, and unmatched know-how to create novel medicines.
Lassen Therapeutics is developing novel, best-in-class biotherapeutics to improve the lives of patients suffering from serious diseases.
Our Science
Our lead program targets interleukin-11, a cytokine which is a central mediator of fibrosis and plays a key role in the tumor microenvironment of certain cancers.
Our Pipeline
Lassen is applying industry-leading antibody technologies to create a pipeline of breakthrough therapeutics.
Our team has a proven track record of building robust antibody development platforms and pipelines and is guided by a set of meaningful and inspirational core values. We are:
- Innovative and adapt to challenges
- Honest and communicate transparently
- Collaborative and treat everyone with respect
- Focused on people – our team, our collaborators, and patients
- Passionate about creating life-improving medicines
-
San Diego, CA, June 15, 2022 – Lassen Therapeutics, a biotech company developing breakthrough antibody therapeutics as potential treatments for fibrosis, rare diseases and oncology, today presented new preclinical data on LASN01, a monoclonal antibody targeting IL-11 receptor (IL-11R), in preclinical models of skin fibrosis at the Keystone Symposia Conference on Tissue Fibrosis and Repair: Mechanisms, Human Disease and Therapies being held in Keystone, Colorado. The data build upon the results in models of lung fibrosis recently presented at the American Thoracic Society (ATS) conference in May.
> Full Story -
San Diego, CA, May 26, 2022 – Lassen Therapeutics, a biotech company developing breakthrough antibody therapeutics as potential treatments for fibrosis, rare diseases and oncology, today announced plans to present a poster on IL-11 receptor-blocking as a novel therapeutic approach for lung fibrosis at the upcoming Keystone Symposia Conference on Tissue Fibrosis and Repair: Mechanisms, Human Disease and Therapies being held in Keystone, Colorado, June 12-16, 2022.
> Full Story -
- LASN01 is a potent inhibitor of IL-11 signaling
- Inhibition of IL-11 receptor shows anti-fibrotic effect in multiple preclinical models
- LASN01 is rapidly advancing toward clinical evaluation